Conventionally, SASP has been interpreted as a failed attempt at immune clearance—a distress signal that should trigger cell removal but becomes chronic when surveillance systems decline. The problem with this framework is that it treats SASP as a single, monolithic inflammatory output. My take is different: SASP represents a bifurcated reparative program with two functionally distinct arms. One is an NF-κB/cGAS-STING–driven immune clearance signal targeting senescent cells themselves. The other is a distinct, partially overlapping signal constellation that recruits progenitor and stem cells to sites of damage for tissue regeneration. With age-dependent epigenetic remodeling at CDKN2A/B and SASP super-enhancers, these two arms become uncoupled—the inflammatory clearance signal persists while the regenerative recruitment component weakens or disappears.

Mechanistic basis: The evidence here is actually pretty compelling. H2A.J accumulation turns out to be specifically required for inflammatory SASP genes but dispensable for senescence maintenance, and CDKN2A-targeted partial reprogramming suppresses SASP without reversing cell cycle arrest. This demonstrates a clear programmatic separation between the growth arrest and inflammatory outputs. I'm extending this by proposing that within SASP itself, distinct epigenetic configurations—potentially involving differential BRD4 occupancy and enhancer diversity at IL1A/IL1B versus chemokine loci—create sub-programs with different tissue-specific effects.

The immune clearance arm, mediated by IL-1β, IL-6, and metalloproteinases, remains active because it's maintained by persistent chromatin states (H3K9me, DNA hypermethylation) that lock cells into a defensive posture. Simultaneously, the stem cell recruitment arm—coordinated through CXCL1, CXCL8, and growth factors—requires additional epigenetic "locks" that fail with age. The result is an asymmetric output where the inflammatory signal persists without the functional repair response it was meant to coordinate.

This uncoupling hypothesis explains why senolytic approaches show benefit: they eliminate the persistent inflammatory signal. But it also predicts that purely anti-inflammatory interventions will prove limited—they suppress the symptom without addressing the missing repair response. More critically, it suggests that SASP itself, when epigenetically reprogrammed to restore the recruitment arm while dampening the inflammatory arm, could become therapeutic rather than pathological.

Testable predictions: First, single-cell ATAC-seq of aged tissues should reveal subpopulations of p16INK4a+ senescent cells with differential accessibility at SASP sub-program enhancers—some retaining both immune and recruitment accessibility, others locked into an immune-only configuration. Second, conditioned media from early-passage versus late-passage senescent fibroblasts will show divergent chemokine profiles: early SASP should recruit mesenchymal stem cells in transwell assays, while late SASP loses this recruitment capacity despite maintained IL-6/IL-8 secretion. Third, BRD4 degradation or BET inhibition at specific time windows will differentially affect SASP sub-programs, allowing dissection of the immune versus recruitment components. Fourth, in vivo, aged mice receiving SASP with restored stem cell recruitment (via engineered chromatin remodeling) combined with senolytic clearance should show superior tissue regeneration compared to senolytics alone.

This hypothesis reframes inflammaging not as inflammation causing damage, but as a system producing one half of a repair signal—the alarm—without the repair crew it summons. The "fire" isn't the disease; it's a message in two parts, and we're only hearing one.